(secondQuint)Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus.

 There are two study phases according to different doses of investigational drug Phase 1:1 investigational group and 1 control group, i.

e.

; investigational drug PB-119 injection 25 mu g group and control drug exenatide group.

 Phase 1: Plan to have 1 or 2 investigational group according to the study result from phase 1, i.

e.

, investigational drug PB-119 injection 50 mu g group and control drug exenatide group.

 Subject Number:18 subjects will be randomized to each group, with equal number of females and males.

 12 subjects will be in PB-119 group, 6 subjects will be in exenatide group.

.

 Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus@highlight

This is a randomized, opened, positive drug-controlled (Exenatide, Byetta), sequential parallel group, multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of twelve once-weekly subcutaneous doses of PB-119 to subjects with type 2 diabetes mellitus (T2DM).

